MA47447A - 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer - Google Patents
2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancerInfo
- Publication number
- MA47447A MA47447A MA047447A MA47447A MA47447A MA 47447 A MA47447 A MA 47447A MA 047447 A MA047447 A MA 047447A MA 47447 A MA47447 A MA 47447A MA 47447 A MA47447 A MA 47447A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- dihydropyridazine
- heteroaryl
- oxo
- carboxamides
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des composés 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide de formule générale (i), dans laquelle x, r1, r2, r3, r4 et r5 sont tels que définis dans la description. L'invention concerne également des procédés de préparation desdits composés, des composés intermédiaires utiles pour préparer lesdits composés, des compositions et des combinaisons pharmaceutiques comprenant lesdits composés, et l'utilisation desdits composés pour fabriquer des compositions pharmaceutiques pour le traitement ou la prophylaxie de maladies, en particulier le cancer ou les maladies avec dérèglement des réponses immunitaires ou d'autres troubles associés aux signaux ahr aberrants, en monothérapie ou en association avec d'autres principes actifs.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17155406 | 2017-02-09 | ||
| EP17202882 | 2017-11-21 | ||
| PCT/EP2018/052627 WO2018146010A1 (fr) | 2017-02-09 | 2018-02-02 | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA47447A true MA47447A (fr) | 2019-12-18 |
| MA47447B1 MA47447B1 (fr) | 2021-02-26 |
Family
ID=61188789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA47447A MA47447B1 (fr) | 2017-02-09 | 2018-02-02 | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US11795164B2 (fr) |
| EP (1) | EP3580211B1 (fr) |
| JP (1) | JP7128826B2 (fr) |
| KR (1) | KR102627266B1 (fr) |
| CN (3) | CN116531380A (fr) |
| AU (1) | AU2018217860B2 (fr) |
| BR (1) | BR112019016497A2 (fr) |
| CA (1) | CA3052718A1 (fr) |
| CL (1) | CL2019002255A1 (fr) |
| CO (1) | CO2019008684A2 (fr) |
| CR (1) | CR20190364A (fr) |
| CU (1) | CU24564B1 (fr) |
| CY (1) | CY1124484T1 (fr) |
| DK (1) | DK3580211T3 (fr) |
| DO (1) | DOP2019000206A (fr) |
| EC (1) | ECSP19057713A (fr) |
| ES (1) | ES2847162T3 (fr) |
| GE (1) | GEP20217281B (fr) |
| HR (1) | HRP20210143T1 (fr) |
| HU (1) | HUE053191T2 (fr) |
| IL (1) | IL268469B (fr) |
| JO (1) | JOP20190193A1 (fr) |
| LT (1) | LT3580211T (fr) |
| MA (1) | MA47447B1 (fr) |
| MX (1) | MX2019009571A (fr) |
| NI (1) | NI201900085A (fr) |
| PE (1) | PE20191496A1 (fr) |
| PH (1) | PH12019501846A1 (fr) |
| PL (1) | PL3580211T3 (fr) |
| RS (1) | RS61401B1 (fr) |
| SA (1) | SA519402422B1 (fr) |
| SG (1) | SG11201907232XA (fr) |
| SI (1) | SI3580211T1 (fr) |
| TW (1) | TWI770113B (fr) |
| UA (1) | UA124507C2 (fr) |
| UY (1) | UY37606A (fr) |
| WO (1) | WO2018146010A1 (fr) |
| ZA (1) | ZA201905902B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190193A1 (ar) | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان |
| CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
| EP3715471A1 (fr) | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ensemble de marqueur de signature d'ahr |
| EP3721894A1 (fr) | 2019-04-10 | 2020-10-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Gène 1 induit par l'interleukine-4 (il4i1) en tant que biomarqueur et ses utilisations |
| CN112724256B (zh) * | 2019-10-28 | 2022-09-16 | 中国农业大学 | 一种高稳定性的磺胺类药物抗体hAb 4D11及其应用 |
| EP3835432A1 (fr) | 2019-12-10 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Gène 1 induit par l'interleukine-4 (il4i1) et métabolites respectifs en tant que biomarqueurs pour le cancer |
| AU2020403801A1 (en) * | 2019-12-16 | 2022-06-02 | Bayer Aktiengesellschaft | Combination of an AhR-inhibitor and an PD1-inhibitor antibody and its use in the treatment of cancer |
| CN115244048A (zh) | 2020-02-26 | 2022-10-25 | 捷豹治疗有限公司 | 可用于调节AhR信号传导的吡啶并嘧啶衍生物 |
| MX2022011826A (es) * | 2020-03-27 | 2022-10-18 | Dong A St Co Ltd | Derivados de aminopirimidina y su uso como moduladores del receptor de hidrocarburos de arilo. |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| WO2022078356A1 (fr) * | 2020-10-15 | 2022-04-21 | 山东轩竹医药科技有限公司 | Inhibiteur d'ahr hétéroaromatique |
| CN114539221A (zh) * | 2020-11-27 | 2022-05-27 | 苏州泽璟生物制药股份有限公司 | 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用 |
| CN114685426A (zh) * | 2020-12-28 | 2022-07-01 | 苏州泽璟生物制药股份有限公司 | 磺酰胺类抑制剂及其制备方法和应用 |
| CN114835687B (zh) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂 |
| WO2023043753A1 (fr) * | 2021-09-14 | 2023-03-23 | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. | Modulateurs des récepteurs d'hydrocarbures 2-aryle ou hétéroaryl-3-oxo-4-carbamide-6-cyclique-dihydropyrazine aryle et leur utilisation dans le traitement de maladies et d'affections |
| AU2022369984A1 (en) | 2021-10-20 | 2024-03-28 | University Of Rochester | Methods and compositions for rejuvenating cns glial populations by suppression of transcription factors |
| WO2024076300A1 (fr) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Composés utiles dans la modulation de la signalisation d'ahr |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| WO2000009488A1 (fr) * | 1998-08-14 | 2000-02-24 | Nihon Nohyaku Co., Ltd. | Derives de pyridazinone |
| JP2000119257A (ja) | 1998-08-14 | 2000-04-25 | Nippon Nohyaku Co Ltd | ピリダジノン誘導体 |
| KR100770327B1 (ko) | 2000-09-18 | 2007-10-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피리다지논 및 트리아지논 화합물류 및 그들의 의약 용도 |
| FR2847253B1 (fr) * | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
| AR057986A1 (es) | 2005-11-21 | 2008-01-09 | Japan Tobacco Inc | Compuesto heterociclico y su uso farmaceutico |
| US20100210649A1 (en) * | 2006-12-21 | 2010-08-19 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
| EP2328586A2 (fr) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Dérivés pyridazinone substitués comme ligands des récepteurs de l'histamine-3 (h3) |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| CN107648216B (zh) | 2010-07-27 | 2021-03-30 | 波士顿大学管理委员会 | 作为新型癌症疗法的芳烃受体(AhR)调节剂 |
| WO2015143164A1 (fr) | 2014-03-19 | 2015-09-24 | President And Fellows Of Harvard College | Agents antimicrobiens et procédés de criblage |
| CA3025227A1 (fr) * | 2016-05-25 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
| JOP20190193A1 (ar) | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان |
| CA3082856A1 (fr) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 3-oxo-2,3-dihydropyridazine-4-carboxamides substitues par du soufre |
-
2017
- 2017-06-16 JO JOP/2019/0193A patent/JOP20190193A1/ar unknown
-
2018
- 2018-02-02 RS RS20210096A patent/RS61401B1/sr unknown
- 2018-02-02 PL PL18703958T patent/PL3580211T3/pl unknown
- 2018-02-02 BR BR112019016497A patent/BR112019016497A2/pt active Search and Examination
- 2018-02-02 GE GEAP201815183A patent/GEP20217281B/en unknown
- 2018-02-02 CN CN202310479983.0A patent/CN116531380A/zh active Pending
- 2018-02-02 KR KR1020197025958A patent/KR102627266B1/ko active IP Right Grant
- 2018-02-02 CA CA3052718A patent/CA3052718A1/fr active Pending
- 2018-02-02 AU AU2018217860A patent/AU2018217860B2/en active Active
- 2018-02-02 JP JP2019542502A patent/JP7128826B2/ja active Active
- 2018-02-02 SG SG11201907232XA patent/SG11201907232XA/en unknown
- 2018-02-02 UA UAA201909559A patent/UA124507C2/uk unknown
- 2018-02-02 EP EP18703958.1A patent/EP3580211B1/fr active Active
- 2018-02-02 MA MA47447A patent/MA47447B1/fr unknown
- 2018-02-02 WO PCT/EP2018/052627 patent/WO2018146010A1/fr unknown
- 2018-02-02 CN CN201880024008.8A patent/CN110678459B/zh active Active
- 2018-02-02 HU HUE18703958A patent/HUE053191T2/hu unknown
- 2018-02-02 CN CN202310485656.6A patent/CN116554152A/zh active Pending
- 2018-02-02 PE PE2019001570A patent/PE20191496A1/es unknown
- 2018-02-02 CR CR20190364A patent/CR20190364A/es unknown
- 2018-02-02 SI SI201830192T patent/SI3580211T1/sl unknown
- 2018-02-02 DK DK18703958.1T patent/DK3580211T3/da active
- 2018-02-02 MX MX2019009571A patent/MX2019009571A/es unknown
- 2018-02-02 ES ES18703958T patent/ES2847162T3/es active Active
- 2018-02-02 CU CU2019000073A patent/CU24564B1/es unknown
- 2018-02-02 LT LTEP18703958.1T patent/LT3580211T/lt unknown
- 2018-02-05 TW TW107104035A patent/TWI770113B/zh active
- 2018-02-09 UY UY0001037606A patent/UY37606A/es not_active Application Discontinuation
-
2019
- 2019-08-04 IL IL268469A patent/IL268469B/en unknown
- 2019-08-08 SA SA519402422A patent/SA519402422B1/ar unknown
- 2019-08-08 PH PH12019501846A patent/PH12019501846A1/en unknown
- 2019-08-09 CO CONC2019/0008684A patent/CO2019008684A2/es unknown
- 2019-08-09 CL CL2019002255A patent/CL2019002255A1/es unknown
- 2019-08-09 DO DO2019000206A patent/DOP2019000206A/es unknown
- 2019-08-09 NI NI201900085A patent/NI201900085A/es unknown
- 2019-08-12 EC ECSENADI201957713A patent/ECSP19057713A/es unknown
- 2019-09-06 ZA ZA2019/05902A patent/ZA201905902B/en unknown
-
2021
- 2021-01-27 HR HRP20210143TT patent/HRP20210143T1/hr unknown
- 2021-01-28 CY CY20211100070T patent/CY1124484T1/el unknown
-
2022
- 2022-08-12 US US17/819,602 patent/US11795164B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47447A (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
| MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
| MA40523B1 (fr) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
| MA41179A (fr) | Composés inhibiteurs de parg | |
| MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
| TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
| MA33604B1 (fr) | Composés et compositions en tant qu'inhibiteurs de protéine kinase | |
| MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
| MA35422B1 (fr) | Imidazopyridazines amino-substituees | |
| MA39219A1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| MA33119B1 (fr) | Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase | |
| MA34308B1 (fr) | Triazolopyridines substituées | |
| MA31952B1 (fr) | Pyrrolopyrimidines et pyrrolopyridines | |
| TNSN07258A1 (fr) | Derives de quinoleine heteroaromatiques et leur utilisation comme inhibiteurs de pde10 | |
| MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
| MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
| MA33726B1 (fr) | Composes de dioxyde d'iminothiadiazine comme inhibiteurs de bace, compositions et leur utlisation | |
| MA37798B1 (fr) | 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes | |
| MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA50391B1 (fr) | Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires |